Cure Today

Bavencio and BSC Extends Survival in Bladder Cancer, Regardless of Diabetes Status

Avelumab plus BSC significantly improved OS and PFS in advanced urothelial carcinoma patients, irrespective of diabetes status, as shown in the JAVELIN Bladder 100 trial. The trial's findings led to ...
Cure Today

Bavencio Has Long-Term Benefit Regardless of Diabetes Status in Bladder Cancer

Bavencio shows efficacy and safety in advanced urothelial carcinoma, regardless of diabetes status, as per JAVELIN Bladder 100 trial findings. Diabetes requires careful management in patients ...
Nasdaq

Relmada Therapeutics Reports Promising Phase 2 Data for NDV-01 in Non-Muscle Invasive Bladder Cancer with 90% of Patients Achieving Disease-Free Status

100% (n=7) of evaluable patients (1 CIS, 6 Ta/T1) achieved disease free status. One of these patients was re-treated at 3 months. “I am impressed by these promising NDV-01 data reported at AUA2025.